In today’s special ‘bite-sized’ Molecule to Market episode, I’ll be talking with Jim Miller about the CDMO space at the half point mark in 2012.

Inspired by this terrific article https://www.dcatvci.org/7173-mid-year-cdmo-review-covid-19-vaccine-manufacturing-and-m-a on the DCAT ValueChain Insights websites, Jim covers:

Vaccine manufacturing, capacity constraints and the increasing scale and role of the CDMO in the pharma space.

32+ M&A deals already and an outlook for more (and bigger) activity on the cards.

Very encouraging trends for CDMOs in terms of funding in the sector, likely preparation for future pandemics and a backlog of clinical trials.

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s a industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.